Reproductive Medicine Center, Department of Obstetrics and Gynecology, the First Affiliated Hospital of Anhui Medical University, Hefei, 230032, China.
NHC Key Laboratory of Study on Abnormal Gametes and Reproductive Tract, Anhui Medical University, Hefei, 230032, China.
BMC Microbiol. 2024 May 17;24(1):169. doi: 10.1186/s12866-024-03329-x.
Polycystic ovary syndrome (PCOS) is an endocrinopathy in childbearing-age females which can cause many complications, such as diabetes, obesity, and dyslipidemia. The metabolic disorders in patients with PCOS were linked to gut microbial dysbiosis. However, the correlation between the gut microbial community and dyslipidemia in PCOS remains unillustrated. Our study elucidated the different gut microbiota in patients with PCOS and dyslipidemia (PCOS.D) compared to those with only PCOS and healthy women.
In total, 18 patients with PCOS, 16 healthy females, and 18 patients with PCOS.D were enrolled. The 16 S rRNA sequencing in V3-V4 region was utilized for identifying the gut microbiota, which analyzes species annotation, community diversity, and community functions. Our results showed that the β diversity of gut microbiota did not differ significantly among the three groups. Regarding gut microbiota dysbiosis, patients with PCOS showed a decreased abundance of Proteobacteria, and patients with PCOS.D showed an increased abundance of Bacteroidota compared to other groups. With respect to the gut microbial imbalance at genus level, the PCOS.D group showed a higher abundance of Clostridium_sensu_stricto_1 compared to other two groups. Furthermore, the abundances of Faecalibacterium and Holdemanella were lower in the PCOS.D than those in the PCOS group. Several genera, including Faecalibacterium and Holdemanella, were negatively correlated with the lipid profiles. Pseudomonas was negatively correlated with luteinizing hormone levels. Using PICRUSt analysis, the gut microbiota community functions suggested that certain metabolic pathways (e.g., amino acids, glycolysis, and lipid) were altered in PCOS.D patients as compared to those in PCOS patients.
The gut microbiota characterizations in patients with PCOS.D differ from those in patients with PCOS and controls, and those might also be related to clinical parameters. This may have the potential to become an alternative therapy to regulate the clinical lipid levels of patients with PCOS in the future.
多囊卵巢综合征（PCOS）是一种育龄女性的内分泌疾病，可导致多种并发症，如糖尿病、肥胖和血脂异常。PCOS 患者的代谢紊乱与肠道微生物失调有关。然而，PCOS 患者的肠道微生物群落与血脂异常之间的相关性尚未阐明。我们的研究阐明了 PCOS 伴血脂异常（PCOS.D）患者与单纯 PCOS 患者和健康女性之间不同的肠道微生物群。
共纳入 18 例 PCOS 患者、16 例健康女性和 18 例 PCOS.D 患者。采用 V3-V4 区 16S rRNA 测序鉴定肠道微生物群，分析物种注释、群落多样性和群落功能。结果显示，三组间肠道微生物群的β多样性无显著差异。关于肠道微生物群失调，与其他两组相比，PCOS 患者的变形菌门丰度降低，PCOS.D 患者的拟杆菌门丰度增加。在属水平的肠道微生物失衡方面，PCOS.D 组的梭状芽孢杆菌属丰度高于其他两组。此外，PCOS.D 组的粪杆菌和霍尔登埃拉菌属丰度低于 PCOS 组。一些属，包括粪杆菌和霍尔登埃拉菌属，与血脂谱呈负相关。假单胞菌与促黄体生成素水平呈负相关。通过 PICRUSt 分析，肠道微生物群群落功能表明，与 PCOS 患者相比，PCOS.D 患者的某些代谢途径（如氨基酸、糖酵解和脂质）发生改变。
PCOS.D 患者的肠道微生物特征与 PCOS 患者和对照组不同，这可能与临床参数有关。这可能有潜力成为未来调节 PCOS 患者临床血脂水平的替代治疗方法。
